FDMT

10.68

1.93% -0.21

Dopo l'orario di chiusura: 10.70 0.02 +0.19%

4 D Molecular Therapeutics Inc (FDMT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$10.89

Aprire:

$10.96

Volume 24 ore:

672.75K

Relative Volume:

0.85

Capitalizzazione di mercato:

$610.20M

Reddito:

$20.72M

Utile/perdita netta:

$-100.84M

Rapporto P/E:

-4.015

EPS:

-2.66

Flusso di cassa netto:

$-78.56M

1 W Prestazione:

+5.85%

1M Prestazione:

-5.82%

6M Prestazione:

+206.02%

1 anno Prestazione:

+40.16%

Intervallo 1D:

$10.54

$11.12

Intervallo di 1 settimana:

$10.09

$11.30

Portata 52W:

$2.235

$12.34

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Nome

4 D Molecular Therapeutics Inc

Settore

Healthcare (1135)

Industria

Biotechnology (635)

Telefono

(510) 505-2680

Indirizzo

5858 HORTON STREET #455, EMERYVILLE

Dipendente

227

Cinguettio

Prossima data di guadagno

2024-12-13

Ultimi documenti SEC

FDMT's Discussions on Twitter

Confronta FDMT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
FDMT 4 D Molecular Therapeutics Inc	10.68	622.20M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	429.82	107.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	787.32	80.03B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	429.80	57.37B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	917.93	55.83B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	209.02	44.13B	447.02M	-1.18B	-906.14M	-6.1812

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-07	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2025-01-13	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-11-21	Iniziato	Morgan Stanley	Underweight
2024-09-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2024-04-15	Iniziato	Barclays	Overweight
2024-02-07	Ripresa	Goldman	Buy
2023-10-26	Iniziato	RBC Capital Mkts	Outperform
2023-10-24	Iniziato	Cantor Fitzgerald	Overweight
2023-10-18	Aggiornamento	Leerink Partners	Market Perform → Outperform
2023-07-05	Iniziato	Chardan Capital Markets	Buy
2023-01-30	Iniziato	BMO Capital Markets	Outperform
2022-11-18	Iniziato	H.C. Wainwright	Buy
2022-11-15	Aggiornamento	Goldman	Neutral → Buy
2022-08-12	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-06-22	Iniziato	Jefferies	Buy
2022-01-04	Iniziato	SVB Leerink	Outperform
2021-01-05	Iniziato	BofA Securities	Buy
2021-01-05	Iniziato	Evercore ISI	Outperform
2021-01-05	Iniziato	Goldman	Neutral

Mostra tutto

4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie

Nov 23, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 23, 2025

Nov 21, 2025

Transcript : 4D Molecular Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09 - MarketScreener

Nov 21, 2025

4D Molecular Therapeutics taps Kristian Humer as CFO - MSN

Nov 21, 2025

Nov 20, 2025

Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock - MarketBeat

Nov 20, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%What's Next? - MarketBeat

Nov 20, 2025

4D Molecular Therapeutics (NASDAQ: FDMT) to join Evercore Healthcare Conference fireside chat - Stock Titan

Nov 20, 2025

Nov 19, 2025

4d Molecular Therapeutics chief legal officer sells $17k in stock - Investing.com Canada

Nov 19, 2025

[Form 4] 4D Molecular Therapeutics, Inc. Insider Trading Activity - Stock Titan

Nov 19, 2025

4D Molecular Therapeutics Executive Sells Shares - TradingView

Nov 19, 2025

Officer Bizily Sells 1,635 ($17.3K) Of 4D Molecular Therapeutics Inc [FDMT] - TradingView

Nov 19, 2025

Published on: 2025-11-19 17:30:27 - newser.com

Nov 19, 2025

Nov 18, 2025

Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail

Nov 18, 2025

4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development - MSN

Nov 18, 2025

What recovery options are there for 4D Molecular Therapeutics Inc.July 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com

Nov 18, 2025

FDMT: 4D-150 achieves up to 92% injection reduction in wet AMD, with global phase III trials underway - TradingView

Nov 18, 2025

FDMT: 4D-150 gene therapy offers up to 92% injection reduction and strong safety for retinal disease - TradingView

Nov 18, 2025

Nov 17, 2025

4D Molecular Therapeutics appoints Kristian Humer as chief financial officer By Investing.com - Investing.com Nigeria

Nov 17, 2025

4D Molecular Therapeutics Names Kristian Humer as CFO - MarketScreener

Nov 17, 2025

4D Molecular Therapeutics appoints Kristian Humer as chief financial officer - Investing.com

Nov 17, 2025

4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer - Quiver Quantitative

Nov 17, 2025

[8-K] 4D Molecular Therapeutics, Inc. Reports Material Event | FDMT SEC FilingForm 8-K - Stock Titan

Nov 17, 2025

4D Molecular Therapeutics (Nasdaq: FDMT) names Kristian Humer CFO to lead finance - Stock Titan

Nov 17, 2025

Nov 16, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen - MarketBeat

Nov 16, 2025

Nov 15, 2025